Early adoption of the update is permitted.
The Company used $1,600 in financing activities in the three months ended September 30, 2018 compared to $144,300 in the three months ended September 30, 2017 due to the contingent consideration paid in the prior year period.
Cash and cash equivalents increased by $454,200 to $1,507,300 as of September 30, 2018 from $1,053,100 as of June 30, 2018.
  6.
As of September 30, 2018 no borrowings were outstanding under such line.
 The Company reflected income tax expense of $35,500 for the three months ended September 30, 2018 compared to a tax benefit of $73,900 for the three months ended September 30, 2017, primarily due to the income generated during the three months ended September 30, 2018.
The Company reflected income before tax expense of $177,500 for the three months ended September 30, 2018 compared to a loss before income tax benefit of $306,500 for the three months ended September 30, 2017, primarily the result of increased revenues across all business segments.
The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments.
Net revenues for the three months ended September 30, 2018 increased $757,800 (59.2%) to $2,038,600 from $1,280,800 for the three months ended September 30, 2017, reflecting an increase of $492,500 (41.1%) in net sales of benchtop laboratory equipment.
  6.
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
All material intercompany balances and transactions have been eliminated.
  The Company has a Demand Line of Credit through December 2018 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at prime, currently 5.25%.
 General and administrative expenses for the three months ended September 30, 2018 amounted to $416,500 compared to $428,400 for the three months ended September 30, 2017 due to various minor decreases in expenses for the Bioprocessing Systems Operations and the Catalyst Research Instruments Operations.
The Company is currently evaluating the impact of the new standard.